EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC-ND 4.0

Acalabrutinib Versus Venetoclax Plus Obinutuzumab in Treatment‐Naive Chronic Lymphocytic Leukemia: A Real‐World Propensity Score‐Matched Study

Po-Wei Liao, Bor-Sheng Ko, Yu-Chen Su, Wei-Ting Chao, Chieh-Lin Jerry Teng

Cancer Medicine · 2026-06 · 15 (6)

DOI: 10.1002/cam4.72022 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Cancer Medicine, online erschienen am 04.06.2026. Verfasst von Po-Wei Liao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Medical Oncology, Department of Medicine, Taichung Veterans General Hospital, Taichung, Taiwan. Hauptthemen laut MEDLINE: Bridged Bicyclo Compounds, Heterocyclic, Sulfonamides, Antibodies, Monoclonal, Humanized, Benzamides. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Taichung Veterans General Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Therapy for chronic lymphocytic leukemia (CLL) has shifted from chemoimmunotherapy to targeted agents such as Bruton's tyrosine kinase (BTK) inhibitors and BCL‐2 inhibitors. Approved first‐line options include acalabrutinib, a second‐generation BTK inhibitor, and the fixed‐duration combination venetoclax–obinutuzumab, yet real‐world head‐to‐head data are scarce.

Methods

Using the TriNetX global federated health database, we retrospectively compared outcomes in treatment‐naïve patients with TP53‐unmutated CLL who received either regimen as initial therapy. After applying eligibility criteria and 1:1 propensity score matching, 669 matched pairs were analyzed. The primary endpoint was time to next treatment (TTNT); secondary endpoints included overall survival (OS) and adverse events.

Results

The results showed that patients treated with venetoclax plus obinutuzumab had a significantly longer TTNT (median not reached vs. 47.7 months) and improved 4‐year OS . Across all subgroups, the venetoclax‐based regimen performed better. Cytopenias and infections were more common with venetoclax–obinutuzumab—neutropenia 54.3% versus 33.3%, thrombocytopenia 45.9% versus 31.9%, febrile neutropenia 7.1% versus 3.4%, and tumor lysis syndrome 6.3% versus 2.3%. Acalabrutinib caused fewer severe hematologic toxicities.

Conclusion

In real‐world practice, venetoclax plus obinutuzumab was associated with longer TTNT and improved OS compared to acalabrutinib as first‐line therapy in patients with TP53 wild‐type CLL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bridged Bicyclo Compounds, HeterocyclicSulfonamidesAntibodies, Monoclonal, HumanizedBenzamidesLeukemia, Lymphocytic, Chronic, B-CellAntineoplastic Combined Chemotherapy ProtocolsPyrazinesHumansPropensity ScoreFemaleMaleAgedRetrospective StudiesMiddle AgedAged, 80 and over

Stichwörter der Autor:innen

CLLTriNetXacalabrutinibobinutuzumabvenetoclax

Substanzen

Bridged Bicyclo Compounds, HeterocyclicacalabrutinibSulfonamidesvenetoclaxobinutuzumabAntibodies, Monoclonal, HumanizedBenzamidesPyrazines

Autor:innen und Institutionen

  • Division of Hematology/Medical Oncology, Department of Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
  • Department of Life Science, Tunghai University, Taichung, Taiwan.
  • School of Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.
  • Department of Hematological Oncology, National Taiwan University Cancer Center, Taipei City, Taiwan.
  • Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei City, Taiwan.
  • Department of Nursing, Taichung Veterans General Hospital, Taichung, Taiwan.

Förderung

  • Taichung Veterans General Hospital

Zitieren

APA

Liao, P. W., Ko, B. S., Su, Y. C., Chao, W. T., & Teng, C. J. (2026). Acalabrutinib Versus Venetoclax Plus Obinutuzumab in Treatment‐Naive Chronic Lymphocytic Leukemia: A Real‐World Propensity Score‐Matched Study. Cancer Medicine, 15(6). https://doi.org/10.1002/cam4.72022

Vancouver

Liao PW, Ko BS, Su YC, Chao WT, Teng CJ. Acalabrutinib Versus Venetoclax Plus Obinutuzumab in Treatment‐Naive Chronic Lymphocytic Leukemia: A Real‐World Propensity Score‐Matched Study. Cancer Medicine. 2026;15(6). doi:10.1002/cam4.72022

BibTeX
@article{Liao2026,
  author = {Liao, Po-Wei and Ko, Bor-Sheng and Su, Yu-Chen and Chao, Wei-Ting and Teng, Chieh-Lin Jerry},
  title = {Acalabrutinib Versus Venetoclax Plus Obinutuzumab in Treatment‐Naive Chronic Lymphocytic Leukemia: A Real‐World Propensity Score‐Matched Study},
  journal = {Cancer Medicine},
  year = {2026},
  volume = {15},
  number = {6},
  doi = {10.1002/cam4.72022}
}
Kostenlos starten →